+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase



Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase



Proceedings of the American Association for Cancer Research Annual Meeting 43: 1080-1081




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034425991

Download citation: RISBibTeXText


Related references

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clinical Cancer Research 9(4): 1546-1556, 2003

Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors Results from a phase I study. European Journal of Cancer 37(Suppl. 6): S73, 2001

Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced antitumor response. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1081, 2002

ZD6474 Design, synthesis and structure activity relationship of a novel, orally active VEGF receptor tyrosine kinase inhibitor. Proceedings of the American Association for Cancer Research Annual Meeting 42: 587, 2001

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clinical Cancer Research 11(3): 1268-1276, 2005

ZD6474 An inhibitor of VEGF receptor tyrosine kinase activity. Clinical & Experimental Metastasis 17(9): 776, 1999( ), 2000

Pharmacological efficacy of ZD6474, a VEGF receptor tyrosine kinase inhibitor in rat. Proceedings of the American Association for Cancer Research Annual Meeting 42: 583, 2001

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Science 95(12): 984-989, 2004

A mechanistic examination of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in vivo. British Journal of Cancer 85(Suppl. 1): 34, 2001

Anti-tumour activity of ZD6474, a VEGF receptor tyrosine kinase inhibitor. British Journal of Cancer 83(Suppl. 1): 31, 2000

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Molecular Cancer Therapeutics 8(11): 3151-3161, 2009

Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clinical Cancer Research 15(9): 3058-3067, 2009

ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Molecular Cancer Therapeutics 3(9): 1041-1048, 2004

Tumour xenograft regression can be induced by combining the vascular-targeting agent ZD6126 with the VEGF receptor tyrosine kinase inhibitor ZD6474. British Journal of Cancer 86(Suppl. 1): S99-S100, 2002

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Design 15(1): 29-41, 2000